News · 26 weeks3+100%
2026-04-262026-10-18
Mix390d
- Other2(67%)
- Offering1(33%)
Latest news
25 items- PRAxonex AI Group Joins FLAIR’s Embodied AI International Applications Hub and Launches Education Humanoid TOMOCollaboration to Explore Real-world Applications in Education and Manufacturing Hong Kong, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Axonex AI Group Limited ("Axonex AI" or the "Company", together with its subsidiaries, the "Group"), a Hong Kong-based company strategically focused on artificial intelligence (AI) and robotics as its primary growth engine, today announced two breakthroughs in its humanoid robots and embodied AI business. Its indirect majority-owned joint venture entity, Rice Robotics (Hong Kong) Limited ("Rice Robotics HK"), has joined the Embodied AI International Applications Hub (the "Hub") as one of its first batch of technology partners. The Hub was officially launched to
- PRAxonex AI Group Limited (NASDAQ: AXNX) Solidifies Transformation into an AI and Robotics-Focused CompanyFormerly Mint Incorporation Limited (NASDAQ:MIMI), the Company Unveils New Corporate Identity and Ticker to Reflect Strategic Focus on AI and Robotics as Its Primary Growth Engine Hong Kong, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mint Incorporation Limited today announced that it has changed the Company's name to Axonex AI Group Limited ("Axonex AI" or the "Company", together with its subsidiaries, the "Group"), as part of its official rebranding. The change of name took effect on September 28, 2026. The Company's Class A ordinary shares are expected to begin trading on the Nasdaq Capital Market under the new ticker symbol "AXNX", at the open of market trading on October 13, 2026. The C
- PRCAIRDAC Announces the Appointment of Raymond W. Cohen as Chairman of its Board of DirectorsCAIRDAC, SA, a pre-revenue stage medtech company developing a leadless, self-powered cardiac pacemaker (Autonomous Leadless Pacing System), today announced the appointment of Raymond W. Cohen as chairman of its board of directors. "We are thrilled to welcome Mr. Cohen to the CAIRDAC board of directors," said Edouard Fonck, Chief Executive Officer of CAIRDAC, "Ray’s extensive track record in leading, scaling and exiting medical technology companies will, no doubt, be invaluable as we advance this exciting project." Mr. Cohen, an accredited public company director and accomplished medical technology executive, has over four decades of medtech industry experience. He was the co-founder and
- PRRxSight, Inc. Appoints Raymond W. Cohen to Its Board of DirectorsALISO VIEJO, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Raymond W. Cohen to its Board of Directors. "We are thrilled to welcome Raymond W. Cohen to the RxSight Board of Directors," said J. Andy Corley, Chairman of the Board at RxSight. "Ray's extensive track record in leading and scaling medical technology companies will be invaluable as we advance our strategy and enter the next phase of growth. His insights and guidance will help us expand the reach of the RxSight® Light Adjustable Lens system,
- SECSEC Form 15-12G filed by Axonics Inc.15-12G - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form EFFECT filed by Axonics Inc.EFFECT - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form 25-NSE filed by Axonics Inc.25-NSE - Axonics, Inc. (0001603756) (Subject)
- INSIDERDirector Kiernan Jane E returned $1,410,131 worth of shares to the company (19,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDEREVP, Chief Mktg/Strtgy Officer Woock John returned $5,495,613 worth of shares to the company (77,403 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Snyderman Nancy Lynn Md returned $1,061,024 worth of shares to the company (14,944 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Operating Officer Sama Rinda returned $5,996,802 worth of shares to the company (84,462 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Medical Officer Noblett Karen returned $2,444,388 worth of shares to the company (34,428 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Lopez Esteban returned $468,600 worth of shares to the company (6,600 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Mcnamara Robert returned $1,055,131 worth of shares to the company (14,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Commercial Officer Ford Alfred J Jr returned $3,084,950 worth of shares to the company (43,450 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Financial Officer Keese Kari Leigh returned $2,865,702 worth of shares to the company (40,362 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Demski David M returned $677,482 worth of shares to the company (9,542 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERChief Executive Officer Cohen Raymond W returned $20,783,901 worth of shares to the company (292,731 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- INSIDERDirector Carrel Michael H returned $1,268,131 worth of shares to the company (17,861 units at $71.00), closing all direct ownership in the company (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
- SECSEC Form POS AM filed by Axonics Inc.POS AM - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form S-8 POS filed by Axonics Inc.S-8 POS - Axonics, Inc. (0001603756) (Filer)
- SECSEC Form S-8 POS filed by Axonics Inc.S-8 POS - Axonics, Inc. (0001603756) (Filer)
- SECAxonics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Axonics, Inc. (0001603756) (Filer)
- PRBoston Scientific Closes Acquisition of Axonics, Inc.MARLBOROUGH, Mass., Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (NASDAQ:AXNX), a medical technology company focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction. "Over the last decade, it has been impressive to see the meaningful innovations Axonics has delivered for patients with overactive bladder and incontinence," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "By closing this acquisiti
- INSIDERDirector Snyderman Nancy Lynn Md gifted 5,000 shares, decreasing direct ownership by 25% to 14,944 units (SEC Form 4)4 - Axonics, Inc. (0001603756) (Issuer)
AXNX FAQ
7 questionsWhat does Axonics Inc. do?
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers...Where does AXNX stock trade?
Axonics Inc. (AXNX) is listed on NASDAQ.What sector and industry is AXNX in?
Axonics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Axonics Inc. go public?
Axonics Inc. (AXNX) completed its IPO in 2018.What are analysts saying about AXNX?
Axonics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2024-01-09.What companies are similar to AXNX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare AXNX side-by-side with any of them on Quantisnow.How can I track AXNX on Quantisnow?
Quantisnow aggregates Axonics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AXNX to receive live email and push alerts on every new disclosure.